BRAFV600E, hypothyroidism, and human relaxin in thyroid carcinogenesis.
Brenda Y HernandezMobeen RahmanLenora W M LooOwen T M ChanDavid HorioShane MoritaGillian Bryant-GreenwoodPublished in: Journal of cancer research and clinical oncology (2020)
Our study provides the first evidence of the potential interaction of BRAFV600E mutation, relaxin, and thyroid hormones in thyroid carcinogenesis. Moreover, our results suggest that hypothyroidism, influenced by RLNH2 activity, may underlie the development of the majority of thyroid cancers and mediate the role of BRAFV600E in thyroid carcinogenesis. BRAFV600E mutation is increasing in papillary thyroid cancers and may be contributing to the rising incidence of this malignancy.